http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics (RLAY) Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Ka Mutations
-
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
-
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
-
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
-
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
-
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
-
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
-
Relay Therapeutics (RLAY) and Foundation Medicine Collaborate for Development of FoundationOne CDX and RLY-4008
-
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
-
Relay Therapeutics (RLAY) Reports New Interim Data for RLY-4008
-
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
-
Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease
-
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
-
Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress
-
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics (RLAY) Discloses Anticipated Registrational Path for RLY-4008
-
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
-
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event
-
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
-
Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
-
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
-
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference
-
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

